Innoviva (INVA) EBIT Growth (3y) (2013 - 2026)
Innoviva (INVA) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.78% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 55.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.50% |
| Dec 31, 2025 | -10.20% |
| Sep 30, 2025 | 20.28% |
| Jun 30, 2025 | 59.11% |
| Mar 31, 2025 | 68.63% |
| Dec 31, 2024 | -20.34% |
| Sep 30, 2024 | -22.96% |
| Jun 30, 2024 | -17.26% |
| Mar 31, 2024 | -12.23% |
| Dec 31, 2023 | -0.64% |
| Sep 30, 2023 | 15.86% |
| Jun 30, 2023 | -34.13% |
| Mar 31, 2023 | -31.71% |
| Dec 31, 2022 | -28.87% |
| Sep 30, 2022 | 5.65% |
| Jun 30, 2022 | -33.93% |
| Mar 31, 2022 | -31.70% |
| Dec 31, 2021 | -27.62% |
| Sep 30, 2021 | 67.42% |
| Jun 30, 2021 | 15.49% |